

Before administering Hemlibra for the first time, you should read the package leaflet contained in the box with your medicine, the guide for patients/carers and patient alert card your doctor or nurse will have provided. You can also go to the Hemlibra data sheet at www.medsafe.govt.nz

Vial preparation

- Have your sharps bin close by
- Take your vial(s) of Hemlibra out of the refrigerator 15 minutes before use
- Check the expiry date and appearance of each Hemlibra vial and your injection supplies before use
- Wash your hands well with soap and water

Injecting

- Use the injection needle to inject medicine
- Inject Hemlibra immediately after preparing the syringe
- After injecting, press a sterile cotton ball or gauze over the injection site for at least 10 seconds if necessary


Reminders

- Only use the syringes and needles provided by your doctor, nurse or haemophilia care team
- Each vial of Hemlibra is for single-use. Discard any partially used vials. Do not save unused medicine for later use
- Use each syringe and needle only once
- Record the name and batch number of each Hemlibra vial that you use
- Talk to your doctor or nurse if you need to combine vials or administer more than one injection to complete your dose
- Use a new transfer needle and alcohol wipe for each vial
- Use a new injection needle for each injection
- Make sure that each injection site is 2.5 cm away from the previous one
- Do not inject more than 2 mL per injection site, if the total volume is greater than 2 mL multiple injections may be needed.

Syringe preparation

- Use the transfer needle to withdraw medicine from the vial
- Once Hemlibra is transferred to the syringe, remove the transfer needle and dispose of it in your sharps bin

Never combine this concentration (blue vial) with any of the other vials.



Do not inject yourself or someone else unless you have been shown how to by your haemophilia care team. For complete injection information please review your patient booklet, administration video or the Instructions for use in the package leaflet.

* By improving the health related quality of life versus bypassing agents.¹
 Reference: 1. Oldenburg J, et al. Haemophilia. 2019 Jan;25(1):33-44
 This item has been developed by Roche Products (New Zealand) Ltd.
 M-NZ-00000125/TAPSNA11034/OCT2020